June 22, 2020 / 2:35 PM / 11 days ago

BRIEF-Gilead Expects Over 2 Mln Remdesivir Treatment Courses Manufactured By Year-End

June 22 (Reuters) - Gilead Sciences Inc:

* GILEAD - IS ABOUT TO START TRIALS OF AN INHALED VERSION OF REMDESIVIR.

* GILEAD - WILL SCREEN HEALTHY VOLUNTEERS FOR PHASE 1 TRIALS THIS WEEK AND HOPE TO BEGIN STUDIES IN PATIENTS WITH COVID-19 IN AUGUST

* GILEAD - NOW EXPECT TO HAVE MORE THAN TWO MILLION REMDESIVIR TREATMENT COURSES MANUFACTURED BY THE END OF THE YEAR AND MANY MILLIONS MORE BY 2021

* GILEAD SAYS ALSO EXPLORING WHETHER IT CAN IMPROVE PATIENT OUTCOMES BY COMBINING REMDESIVIR WITH OTHER THERAPIES - CEO LETTER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below